Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China

BACKGROUND: Real-world data of Palbociclib are insufficient in China. This study aimed to investigate the treatment pattern and real-world outcomes in hormone receptor positive and human epidermal growth factor 2 receptor negative (HR+/HER2-) metastatic breast cancer (MBC) patients treated with Palb...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jiao, Zhao, Bing, Ling, Xiaoling, Li, Donghui, Zhao, Jiuda, Lv, Yonggang, Wang, Guangxi, Liu, Xinlan, Li, Nanlin, Yang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885675/
https://www.ncbi.nlm.nih.gov/pubmed/36717797
http://dx.doi.org/10.1186/s12885-023-10568-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885675/
https://www.ncbi.nlm.nih.gov/pubmed/36717797
http://dx.doi.org/10.1186/s12885-023-10568-0

Ejemplares similares